Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 1.71B +2.6% |
| Revenue (ttm) | 66.05M +78.3% |
| Net Income | -422.60M |
| EPS | -7.25 |
| Shares Out | 59.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 747,398 |
| Open | 28.21 |
| Previous Close | 28.42 |
| Day's Range | 28.08 - 28.87 |
| 52-Week Range | 22.24 - 46.00 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 38.63 (+34.27%) |
| Earnings Date | Apr 29, 2026 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price target is $38.63, which is an increase of 34.27% from the latest price.
News
Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat
Agios Pharmaceuticals (AGIO) announced the submission of its supplemental New Drug Application to the U.S. FDA for the U.S. accelerated approval of mitapivat, an oral pyruvate kinase activator, in sic...
Agios Pharmaceuticals to present mitapivat data at EHA Congress
Agios Pharmaceuticals (AGIO) announced that new data on mitapivat, an oral pyruvate kinase activator, will be featured in oral and poster presentations during the 31st European Hematology Association ...
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing...
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 202...
Agios Pharmaceuticals price target lowered to $36 from $39 at Truist
Truist lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $36 from $39 and keeps a Buy rating on the shares. The company’s Q1 earnings included a more rapid…
Agios Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 138% revenue growth to $20.7M, driven by a strong AQVESME launch in thalassemia and robust U.S. demand. Mitapivat sNDA for sickle cell disease is on track for Q2, and the pipeline remains catalyst-rich with key data readouts expected this year.
Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)
Reports Q1 revenue $20.75M, consensus $13.65M. Reports Q1 Cash, cash equivalents, and marketable securities $1.045B. “Our Q1 performance reflects strong execution and significant progress against our ...
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025 Strong initial U.S. commercial ...
Agios Pharmaceuticals price target lowered to $41 from $44 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $41 from $44 and keeps a Buy rating on the shares. While the firm notes Agios…
H.C. Wainwright cuts Agios target on smaller market post Novo data
H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $50 from $65 and keeps a Buy rating on the shares. Novo Nordisk’s (NVO) Phase…
Agios Pharmaceuticals falls -23.4%
Agios Pharmaceuticals (AGIO) is down -23.4%, or -$8.24 to $26.90.
Agios Pharmaceuticals falls -23.7%
Agios Pharmaceuticals (AGIO) is down -23.7%, or -$8.32 to $26.82.
Agios sinks after Novo Nordisk reports sickle cell data
Shares of Agios Pharmaceuticals (AGIO) are sinking after Novo Nordisk (NVO) reported positive data in sickle cell disease. Novo’s etavopivat showed a 27% reduction in vaso-occlusive crisis events and ...
Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan
JPMorgan raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $36 from $31 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first…
Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan
JPMorgan raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $36 from $31 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first…
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wi...
Agios Pharmaceuticals price target raised to $32 from $28 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $32 from $28 and keeps a Neutral rating on the shares. Shares rose after announcing…
Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
Leerink thinks Agios Pharmaceuticals’ (AGIO) announcement that it is filing mitapivat for accelerated approval in sickle cell disease has positive readthrough to Fulcrum Therapeutics (FULC) by demonst...
PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake
With physicians identifying up to one-third of patients as candidates, early adoption reflects strong enthusiasm tempered by cautious real-world uptake. With physicians identifying up to one-third of ...
Agios Pharmaceuticals to pursue U.S. accelerated approval for mitapivat
Agios Pharmaceuticals (AGIO) announced that it will pursue U.S. accelerated approval for mitapivat, an oral pyruvate kinase activator, in sickle cell disease, following completion of its pre-supplemen...
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat sNDA in sickle cell disease in the coming mo...
Citi ups Agios target, opens ‘upside 90-day catalyst watch’
Citi raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $46 from $38 and keeps a Buy rating on the shares. Citi also placed an “upside 90-day catalyst watch”…
Agios Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Mitapivat’s launch in thalassemia is off to a strong start, with expansion into sickle cell disease and other indications underway. Regulatory updates and key data readouts are expected throughout the year, while commercial focus remains on the U.S. market and broadening patient access.
Agios Pharmaceuticals Pyrukynd approved for adults in UAE
Agios Pharmaceuticals (AGIO) announced that the Emirates Drug Establishment, EDE, of the United Arab Emirates, UAE, has approved Pyrukynd, an oral pyruvate kinase activator, for the treatment of adult...
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty compan...